In the clinical trial, allogeneic DCs directly presented tumor antigens on allogeneic MHC class I and II to recipient T cells, leveraging the alloimmune response as a natural adjuvant to enhance CD8+ and CD4+ T cell activation. This evidence concerns the gene CD8A and neoplasm.